The University of Massachusetts Medical School received a $769,201 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant, awarded on December 16, 2024, supports research to discover optimal combinations of Bacillus thuringiensis (Bt) crystal proteins and small molecule anthelmintic drugs to suppress drug resistance and improve efficacy against parasitic gastrointestinal nematodes that infect an estimated 1.5 billion people globally. The research aims to identify synergistic interactions and collateral sensitivity relationships between 6 Bt crystal proteins and 3 small molecule drugs (albendazole, ivermectin, emodepside) to develop improved treatment options for hookworms, whipworms, and roundworms. This work is intended to provide durable solutions for controlling these parasitic infections and reducing the significant morbidity they cause, especially in children, pregnant women, and working adults.